BioMarin Pharmaceutical appointed Ian T. Clark as Chair of the Board, effective after the June 2, 2026 Annual Meeting, succeeding Richard A. Meier who is retiring after two decades of service. Clark brings extensive leadership experience from the biopharmaceutical industry, including as former CEO of Genentech. Meier's tenure saw significant profitability and growth for BioMarin. The leadership change comes as BioMarin expands globally and integrates recent acquisitions, aiming to enhance value for stakeholders and patients worldwide.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Gold and silver prices are under pressure ahead of key U.S. retail sales data that could influence Federal Reserve interest rate decisions. Central banks, led by Poland and China, continue to boost gold reserves, adding 41 tonnes in May, supporting l...
